Saccharomyces boulardii in the treatment and prevention of antibiotic-associated diarrhea

被引：0

作者：

George Micklefield

机构：

[1] Medizinische Klinik, Evangelisches Krankenhaus Unna, Bösenseller Str. 18a, Münster

来源：

MMW - Fortschritte der Medizin | 2014年 / 156卷 / Suppl 1期

关键词：

Antibiotic-associated diarrhea; Clostridium difficile; Prevention; Probiotics; Saccharomyces boulardii;

D O I：

10.1007/s15006-014-2878-0

中图分类号：

学科分类号：

摘要：

Background: Antibiotic-associated diarrhea (AAD) is the most frequent side effect of antibiotic therapy. Clinical signs and symptoms comprise mild and self- limiting courses of diarrhea as well as life threaten- ing courses like pseudomembranous colitis or toxic megacolon. Therapy is symptomatic, antidiarrheal drugs like Saccharomyces boulardii are the therapy of choice. Method: Available studies on S. boulardii in the prevention of AAD are presented as a review. Results: In 14 out of 17 studies including 4,627 patients the administration of S. boulardii achieved a protective effect between 43.7% and 87.3%. A meta- analysis (5 studies, 1,076 patients) showed a significant reduction of the risk to develop an AAD from 17.2% to 6.7%, in a further meta-analysis (4 studies on eradication of H. pylori, 1.215 patients) the significant reduction was from 12.2% to 5.6%. Conclusions: There is very good evidence for the yeast S. boulardii to be effective in the prevention of AAD especially in hospitalized adults. The simultaneous administration of S. boulardii to antibiotics resulted in a significant reduction to develop AAD by more than half. © 2014 Springer Medizin. All rights reserved.

引用

页码：18 / 22

页数：4

共 36 条

[11]

Adam J., Barret A., Barret-Bellet C., Essais cliniques contrôlés en double insu de l’ultra-levure lyohilisée: Étude multicentrique par 25 médicins de 388 cas, Gaz Med Fr, 84, pp. 2072-2078, (1977)

[12]

Benhamou P.H., Berlier P., Danjou G., Plique O., Jessueld D., Dupont C., La diarrhea associée aux antibiotiques chez l’enfant: Une etude informatisée en double aveugle chez des patients ambulatoires comparant un agent protecteur et un agent probiotique, Méd Chir Dig, 28, pp. 163-168, (1999)

[13]

Bravo M.V., Bunout D., Leiva L., Et al., Effect of probiotic Saccharomyces boulardii on prevention of antibiotic-associated diarrhea in adult outpatients with amoxicillin treatment, Rev Med Chil, 136, pp. 981-988, (2008)

[14]

Can M., Besirbellioglu B.A., Avci I.Y., Beker C.M., Pahsa A., Prophylactic Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea: A prospective study, Med Sci Monit, 12, pp. I19-I22, (2006)

[15]

Cindoruk M., Erkan G., Karakan T., Dursun A., Unal S., Efficacy and safety of Saccharomyces boulardii in the 14-day triple anti-Helicobacter pylori therapy: A prospective randomized placebo-controlled double-blind study, Helicobacter, 12, pp. 309-316, (2007)

[16]

Cremonini F., Di Caro S., Covino M., Et al., Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: A parallel group, triple blind, placebo-controlled study, Am J Gastroenterol, 97, pp. 2744-2749, (2002)

[17]

Duman D.G., Bor S., Ozutemiz O., Et al., Efficacy and safety of Saccharomyces boulardii in prevention of an tibiotic-associated diarrhoea due to Helicobacterpy-lori eradication, Eur J Gastroenterol Hepatol, 17, pp. 1357-1361, (2005)

[18]

Erdeve O., Tiras U., Dallar Y., The probiotic effect of Saccharomyces boulardii in a pediatric age group, J Trop Pediatr, 50, pp. 234-236, (2004)

[19]

Hurduc V., Plesca D., Dragomir D., Sajin M., Vandenplas Y., A randomized, open trial evaluating the effect of Saccharomyces boulardii on the eradication rate of Helicobacter pylori infection in children, Acta Paediatr, 98, pp. 127-131, (2009)

[20]

Kotowska M., Albrecht P., Szajewska H., Saccharomy-ces boulardii in the prevention of antibiotic-associa-ted diarrhoea in children: A randomized double-blind placebo-controlled trial, Aliment Pharmacol Ther, 21, pp. 583-590, (2005)

← 1 2 3 4 →